key: cord-0703107-vhl5adaw authors: Su, Qiu-dong; Yi, Yao; Zou, Ye-ning; Jia, Zhi-yuan; Qiu, Feng; Wang, Feng; Yin, Wen-jiao; Zhou, Wen-ting; Zhang, Shuang; Yu, Peng-cheng; Bi, Sheng-li; Shen, Li-ping; Wu, Gui-zhen title: The biological characteristics of SARS-CoV-2 Spike protein Pro330-Leu650 date: 2020-04-30 journal: Vaccine DOI: 10.1016/j.vaccine.2020.04.070 sha: 375172cc6fbd8e34c8b90b8f40d66ff7b800a5cb doc_id: 703107 cord_uid: vhl5adaw Abstract SARS-CoV-2 is the cause of the worldwide outbreak of COVID-19 that has been characterized as a pandemic by the WHO. Since the first report of COVID-19 on December 31, 2019, 179,111 cases were confirmed in 160 countries/regions with 7,426 deaths as of March 17, 2020. However, there have been no vaccines approved in the world to date. In this study, we analyzed the biological characteristics of the SARS-CoV-2 Spike protein, Pro330-Leu650 (SARS-CoV-2-SPL), using biostatistical methods. SARS-CoV-2-SPL possesses a receptor-binding region (RBD) and important B (Ser438-Gln506, Thr553-Glu583, Gly404-Aps427, Thr345-Ala352, and Lys529-Lys535) and T (9 CD4 and 11 CD8 T cell antigenic determinants) cell epitopes. High homology in this region between SARS-CoV-2 and SARS-CoV amounted to 87.7%, after taking the biological similarity of the amino acids into account and eliminating the receptor-binding motif (RBM). The overall topology indicated that the complete structure of SARS-CoV-2-SPL was with RBM as the head, and RBD as the trunk and the tail region. SARS-CoV-2-SPL was found to have the potential to elicit effective B and T cell responses. Our findings may provide meaningful guidance for SARS-CoV-2 vaccine design. 1 neutralizing antibodies can fully block viral entry into host cells; however, the general 2 location of the binding of other antibodies would strongly affect the body's ability to 3 produce neutralizing antibodies [7] . To date, no coronavirus vaccine has been approved 4 [10] . Inactivated SARS-CoV has been demonstrated to offer incomplete protection, 5 whereas purified coronavirus spike protein nanoparticles have been found to induce 6 coronavirus neutralizing antibodies in mice [10] . Therefore, full exposure of neutralizing 7 epitopes with other B cell epitopes are likely to represent important factors in coronavirus 8 vaccine design. The high homology of the S protein between SARS-CoV-2 and SARS-CoV resulted in 10 the design of a subunit vaccine for SARS-CoV-2, which is focused on the RBD region 11 and its vicinity. For the purpose of vaccine design, we analyzed the biological 12 characteristics (e.g., homology analysis, T and B cell epitope prediction, and advanced The B cell epitopes of SARS-CoV-2-SPL were predicted online with DiscTope2 [11] 23 and IEDB [12] . A DiscTope score peak chart was subsequently constructed using 7 1 in the RBD region, whereas two were located in the tail region. As expected, there were 2 also five motifs in the SARS-CoV-SPL, Thr425-Gln492 (Thr433, 2.403; Thr486, 0.943), 3 Leu538-Leu571 (Arg544, 1.618), Val389-Asp414 (Val404, -1.604), Thr332-Trp340 4 (Ala339, -5.031), and Thr517-Lys521 (Asp518, -8.507) (Fig. 1B) . Furthermore, the two 5 DiscoTope score peaks were almost mirror images (Fig. 1) . According to the MARIA percentiles for all possible 15 mer peptide sequences and 7 NetMHCpan4 percentiles for all possible 9 mer peptide sequences for SARS-CoV-2-SPL, 8 broad coverage was defined as being presented by 1/3 of MHC alleles [8] . We found that 9 15 CD4 epitopes and 17 CD8 T cell epitopes met this requirement. After overlapping 10 integration, there were nine potential CD4 and 11 potential CD8 T cell antigenic 11 determinants (Table 1 ). The RBD region possessed seven CD4 epitopes and nine CD8 T 12 cell epitopes, whereas the tail region has two CD4 epitopes and two CD8 T cell epitopes. 13 Moreover, when comparing these epitopes with verified CD4 and CD8 T cell epitopes of 14 SARS-CoV-SPL [16] , a one-to-one correspondence was observed (e.g., Ser516-Asn530 16 Lys411-Val420 (SARS-CoV) to Lys424-Val433 (SARS-CoV-2). The amino acid identity was 76.25% between SARS-CoV-2-SPL and SARS-CoV-SPL 19 (Fig. 2 ). There were 76 amino acid differences between them, 36 of which were located 20 in the receptor-binding motif (RMB) (Ser438-Gln506), accounting for 47.4% (36/76). 21 Empirically, the biological characteristics of some amino acids (e.g. Arg-Lys, Thr-Ser, 22 Glu-Asp, and Ile-Leu) were similar. After taking the biological similarity of amino acids 1 appear similar to a goldfish, with RMB as the head, RBD as the trunk, and remainders as 2 the tail ( Fig. 3A and 3B ). The RMB (head; critical for receptor binding) of 3 SARS-CoV-2-SPL was completely exposed on the surface (Fig. 3A) , which is also 4 crucial for the production of neutralizing antibodies. Homotrimer SARS-CoV-2-SPL was 5 arranged in a barrel with three RBMs on the top (Fig. 3A) , which might represent the 6 natural state of the SARS-CoV-2-SPL structure. Seventeen years after SARS, 5 the current outbreak of coronavirus disease (COVID-19) caused by SARS-CoV-2, which 6 has a high similarity with SARS-CoV, has shocked the world SARS-CoV-2 has infected 179,111 people, involving 160 countries/regions worldwide, 8 whereas China bears a significant burden However, the evolution of SARS-CoV-2 has continued, with the identification 10 of two major strains, type L (approximately 70%) and type S (approximately 30%) Middle East respiratory syndrome) MERS-CoV, bat SARSr-CoV, and others -2 has a positive, single-strand RNA genome that is over 29 kilobases in 14 length SARS-CoV-2 encodes four major structural proteins, the spike (S), 15 membrane (M), envelope (E), and nucleocapsid (N) proteins The S protein is the 16 most likely target of neutralizing antibodies as it is the main trans-membrane 17 glycoprotein responsible for receptor-binding and virion entry Humoral immunity mediated by antibodies produced by B cells is critical for effective 21 vaccines, whereas cellular immunity mediated by T cells (CD4 and CD8 T cells) is also 22 considered to be essential The CD4 T cell response is critical to both antibody Cys538-Cys590, and Cys617-Cys649). Correspondingly, the 4 SARS-CoV-SPL monomer also had six disulfide bonds Furthermore, the six pairs of cysteines from the two coronaviruses were 7 located at the same position in both the primary (Fig. 2) and tertiary (Fig. 3) structures The structural differences 10 of the trunk, especially the head, were obvious (e.g., the head and trunk of 11 SARS-CoV-2-SPL appeared to be more compact than those of SARS-CoV-SPL), 12 whereas the tail region was highly similar (Fig. 3) The acquisition of SARS-related antigen provides the basis for SARS-CoV-2 vaccine 15 candidate preparation we prepared an 17 insoluble SARS-related antigen with high antigenicity using prokaryotic expression, 18 chromatography purification, and an in-house dialysis procedure. Moreover, the 19 immunogenicity of this SARS-related antigen was also preliminarily confirmed 20 (unpublished) SARS-CoV-2-SPL is likely to seriously hinder the correct folding of the protein Based on the knowledge gained from SARS-CoV vaccine development SARS-CoV-2 vaccine should target the structural proteins, particularly the RBD region The RBD of SARS-CoV-2 and SARS-CoV possesses a similar structure Therefore, many SARS-related studies 10 may provide a valuable reference for SARS-CoV-2 vaccine development Amino acid sequence variations between the RBD of the SARS-CoV-2 spike protein 12 RBD and other coronaviruses have been elucidated completely Despite the high 13 sequence homology with the SARS-CoV spike protein (approx. 76%) RBD-specific antibodies could not bind to SARS-CoV-2 In this study, our focus was centered on SARS-CoV-2-SPL, which was 17 found to contain the RBD and skeleton supporting its conformation. Furthermore, we between SARS-CoV and SARS-CoV-2. The similar protein skeleton was 20 suggestive of a similar protein structure and procedure of prokaryotic expression and 21 chromatography purification The recognition of effective B cell epitopes is dependent on antigenicity, 3 accessibility of the surface and assistance of T helper (CD4 T) cells. CD4 T cells are the 4 main components of the immune system found to impart immunological 'memory' to the 5 new strains. Pathogen-specific T cell responses are also required for protection against 6 infection [23]. In addition, a specific cellular response is considered to be equally 7 important for sustainable protection and pathogen elimination, and CD4 T cells assist in 8 promoting the production of antibodies and CTL reactions. The SARS-CoV-2-SPL was 9 found to possess 5 B cell epitopes, 15 CD4 T cell epitopes In addition, the RBD region of the SARS-CoV-2-SPL appeared to be compact, which 13 might explain why SARS-CoV-2 RBD exhibited a stronger affinity with ACE [5]. The 14 preparation of SARS-CoV-2-SPL was successfully performed in our laboratory However, further neutralization experiments demonstrated that antibodies other than 17 neutralizing antibodies were predominantly generated. In this circumstance, 18 antibody-dependent enhancement (ADE) may exist, which would enhance viral invasion Thus, a potential vaccine antigen should not contain too many epitopes, especially B cell 20 epitopes. Deleting unnecessary B cell epitopes or inserting neutralizing epitopes to The 3 2019-new coronavirus epidemic: Evidence for virus evolution A novel Coronavirus from 6 patients with pneumonia in China WHO. Coronavirus disease 2019 (COVID-19) Situation Report -57 On the origin and continuing 12 evolution of SARS-CoV-2 Crystal structure of the 2019-nCoV 15 spike receptor-binding domain bound with the ACE2 receptor Genomic characterisation and 18 epidemiology of 2019 novel coronavirus: implications for virus origins and receptor 19 binding Cryo-EM 22 structure of the 2019-nCoV spike in the prefusion conformation Potential T-cell and B-cell Epitopes of 2019-nCoV Vaccines and global health: In search of a mice Reliable B cell epitope 5 predictions: impacts of method development and improved benchmarking The 8 Immune Epitope Database (IEDB): 2018 update NetMHCpan-4.0: 11 Improved peptide-MHC Class I interaction predictions integrating eluted ligand and 12 peptide binding affinity data Predicting 15 HLA class II antigen presentation through integrated deep learning Toward the estimation of the absolute quality of 18 individual protein structure models Memory T cell 21 responses targeting the SARS coronavirus persist up to 11 years post-infection Cloning and 24 expression of SARS coronavirus spike gene fragment and its application Potent binding of 2019 novel of SARS-CoV-2 Potent human neutralizing 4 antibodies elicited by SARS-CoV-2 infection Characterization of spike glycoprotein 7 of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Epitope discovery and 10 their use in peptide based vaccines Multi-epitope vaccine design 13 using an immunoinformatics approach for 2019 novel coronavirus in China